Baseline characteristics of the patients included in the two cohorts as well as in the two subsamples: subsample 1 includes patients from four BIOBADASER centres, subsample 2 was drawn randomly from EMECAR to match with the BIOBADASER subsample (see Methods: propensity score)
Descriptor | BIOBADASER(n = 789) | Subsample 1(n = 67) | EMECAR(n = 789) | Subsample 2(n = 67) |
---|---|---|---|---|
*p<0.01 between EMECAR and BIOBADASER. | ||||
†p<0.01 between EMECAR and BIOBADASER subsamples. | ||||
‡p<0.01 between EMECAR and BIOBADASER subsamples. | ||||
Age (years), mean (SD) | 59 (13) | 53 (13) | 61 (13)*† | 52 (11) |
Women, n (%) | 621 (79) | 54 (81) | 568 (72)* | 56 (84) |
Disease Activity Score, mean (SD) | 6.1 (1.2) | 4.2 (1.4)† | 5.9 (1.1) | |
Treated with methotrexate, n (%) | 20 (71) | 546 (70) | 62 (93) | |
Hypercholesterolaemia, n (%) | 14 (30) | 241 (31) | 15 (22) | |
Diabetes, n (%) | 3 (7) | 70 (9) | 6 (9) | |
Hypertension, n (%) | 12 (26) | 286 (37) | 19 (28) | |
Smoking habit, n (%) | 4 (9) | 239 (30)† | 21 (31)‡ | |
Obesity, n (%) | 10 (24) | 160 (21) | 13 (19) |